An interventional study of Radiofrequency Ablation of Papillary Thyroid Cancer and VIVA combo RF Generator with Coagulation Electrode in Thyroid Papillary Carcinoma, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Treatment
This pilot, single-arm clinical study evaluates the feasibility, safety, and effectiveness of radiofrequency ablation (RFA) as a curative treatment for small, low-risk papillary thyroid cancer (PTC). The study will enroll 30 adult patients (≥18 years) with biopsy-confirmed PTC measuring \<2 cm, who decline surgery or active surveillance, or who are transitioning from active surveillance to active treatment.
Eligible participants will undergo ultrasound-guided RFA performed with curative intent at University Health Network. Patients will be followed for up to 12 months with scheduled clinical visits, neck ultrasounds, blood tests, voice assessments, and patient-reported outcome questionnaires. A biopsy of the ablation site at 6-12 months will be used to assess local cancer control.
The primary objective is to determine the local cure rate and safety profile of RFA for low-risk PTC. Secondary objectives include evaluating post-ablation ultrasound features, patient-reported quality of life, and the feasibility of implementing a multidisciplinary thyroid RFA program within routine clinical practice.
Results from this study will provide important preliminary data to inform future larger trials comparing RFA with surgery and active surveillance for selected patients with low-risk papillary thyroid cancer.
This study is a pilot clinical trial designed to evaluate a less invasive treatment option for adults with small, low-risk papillary thyroid cancer (PTC). PTC is the most common type of thyroid cancer and is often slow growing with an excellent prognosis. Standard treatment usually involves surgery to remove part or all of the thyroid gland. While surgery is highly effective, it may be associated with complications such as voice changes, low calcium levels, prolonged recovery, and the need for lifelong thyroid hormone replacement. For some patients, close monitoring without treatment (active surveillance) is an option, but this approach can cause ongoing anxiety and uncertainty.
Radiofrequency ablation (RFA) is a minimally invasive, image-guided procedure that uses controlled heat to destroy targeted tissue. RFA has been widely used to treat benign thyroid nodules and is increasingly being explored as a treatment for carefully selected small thyroid cancers. This study aims to determine whether RFA can safely and effectively eliminate small PTCs while preserving the thyroid gland and reducing the impact of treatment on patients' daily lives.
The study will enroll 30 adult participants (18 years or older) with biopsy-confirmed papillary thyroid cancer measuring less than 2 cm, with no evidence of spread outside the thyroid or to lymph nodes. All participants will have previously been offered standard treatment options and have chosen not to undergo surgery or active surveillance, or will be transitioning from active surveillance to active treatment. Each potential participant will be reviewed by a multidisciplinary team that includes radiology, endocrinology, and surgical specialists to ensure the treatment is appropriate and safe.
The RFA procedure will be performed on an outpatient basis under local anesthesia and light sedation, using real-time ultrasound guidance to precisely target the cancer while protecting nearby structures such as the vocal cords, trachea, and esophagus. Patients are typically observed briefly after the procedure and can return home the same day.
Following treatment, participants will be followed closely for up to 12 months. Follow-up includes clinic visits, neck ultrasound examinations, blood tests to assess thyroid function, voice assessments, and questionnaires that evaluate symptoms, quality of life, satisfaction with treatment, and decision-related concerns. A key component of follow-up is an ultrasound-guided biopsy of the treated area performed 6 to 12 months after RFA, which will be used to determine whether the cancer has been successfully eradicated.
The primary focus of the study is to assess local cancer control and safety of RFA, including the frequency and severity of any complications. Additional goals include understanding how treated thyroid cancers appear on ultrasound over time, evaluating patient-reported outcomes, and assessing the practicality of delivering and sustaining a multidisciplinary thyroid RFA program within a Canadian academic health-care setting.
The results of this study will provide important early evidence on the role of radiofrequency ablation as a potential alternative to surgery for selected patients with low-risk papillary thyroid cancer and will help guide future larger clinical trials and treatment guidelines.
175 studies on the registry are indexed under Thyroid Cancer, Papillary; 52 are open to participants now.
This study's planned enrollment of 30 is below the median of 50 across 108 interventional studies indexed under Thyroid Cancer, Papillary.
Browse Thyroid Cancer, Papillary studies →University Health Network, Toronto is the lead sponsor of 1,411 studies on the registry; 292 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
This single study arm includes adult participants with biopsy-confirmed, low-risk papillary thyroid cancer (\<2 cm) who undergo curative-intent radiofrequency ablation (RFA) of the thyroid tumor. RFA is performed once, on an outpatient basis, using a percutaneous, ultrasound-guided approach with an internally cooled radiofrequency electrode. The procedure is carried out under local anesthesia with conscious sedation, using a standardized moving-shot technique, with hydrodissection as needed to protect adjacent structures. No study drugs are administered as part of this intervention. The RFA procedure is a one-time treatment, although repeat ablation may be considered if residual disease is identified during follow-up, based on clinical judgment and participant consent. All participants in this arm follow the same post-procedure monitoring and follow-up schedule, which includes clinical assessments, neck ultrasound, thyroid blood tests, voice evaluation, patient-reported outcome quest
Procedure: Radiofrequency Ablation of Papillary Thyroid Cancer · Device: VIVA combo RF Generator with Coagulation Electrode
Radiofrequency ablation (RFA) is a minimally invasive, image-guided procedure used to destroy targeted thyroid cancer tissue using controlled heat. In this study, RFA is performed percutaneously under real-time ultrasound guidance using an internally cooled radiofrequency electrode inserted into the thyroid tumor through the skin. The procedure is carried out under local anesthesia with conscious sedation. A standardized moving-shot technique is used to ablate the entire tumor, and hydrodissection may be applied to protect nearby critical structures such as the vocal cord nerve, trachea, and esophagus. RFA is delivered as a single-session treatment with curative intent and is performed on an outpatient basis, with most patients returning home the same day. This intervention preserves the thyroid gland and avoids surgical incisions. Treatment response is assessed through follow-up imaging, clinical evaluations, patient-reported outcomes, and an ultrasound-guided biopsy of the treated
Evaluating the Feasibility, Safety and Efficacy of Radiofrequency Ablation (RFA) for Curative Treatment of Small Low-Risk Thyroid Papillary Cancer: A Pilot Single Arm Clinical Trial - VIVA combo RF Generator with Coagulation Electrode
Also known as: Southmedic Inc,
Local Cure Rate of Papillary Thyroid Cancer (PTC) following Radiofrequency
Local cure rate of papillary thyroid cancer (PTC) following radiofrequency ablation, assessed by ultrasound-guided fine needle aspiration or core biopsy of the ablation site at 6-12 months, with local cure defined as no evidence of malignancy on biopsy (when diagnostic material is obtained).
Time frame: From enrollment to the end of treatment at 12 months.
Safety of the RFA procedure
Safety of the RFA procedure, measured by the incidence and nature of procedure-related complications, including but not limited to voice changes, hematoma, pain, skin burns, and other adverse events.
Time frame: From enrollment to the end of treatment at 12 months.
Ultrasound characteristics following RFA
including features used to differentiate successfully treated tumors from residual or recurrent disease
Time frame: From enrollment to the end of treatment at 12 months
Tumor volume change over time,
measured by volume reduction ratio (VRR)
Time frame: at 6 and 12 months post-RFA
Complication rate of radiofrequency ablation, including but not limited to:
Voice changes, Hematoma, Pain, and Skin burns
Time frame: From Treatment to the end of study at 12 months
Patient-reported outcome (Patient Satisfaction)
Patient satisfaction will be assessed using a study-specific questionnaire evaluating satisfaction with the procedure and overall care. Scores range from 1 to 5, with higher scores indicating greater satisfaction (better outcome) and lower scores indicating lower satisfaction.
Time frame: From enrollment to the end of study at 12 months.
Patient-reported outcome Voice Handicap Index-10 (VHI-10)
Self-reported Voice Handicap Index-10 (VHI-10): Total score range 0-40; higher scores indicate worse voice-related handicap.
Time frame: Time Frame: From enrollment to the end of study at 12 months.
Patient-reported outcome (EORTC QLQ-C30)
The EORTC QLQ-C30 is a validated cancer-specific questionnaire assessing global health status and multiple functional and symptom domains. Scores are transformed to a 0-100 scale. For functional and global health status scales, higher scores indicate better quality of life/functioning, whereas for symptom scales, higher scores indicate worse symptom burden.
Time frame: From enrollment to the end of the study at 12 months
Patient Reported outcome - The Assessment of Survivor Concerns (ASC)
The Assessment of Survivor Concerns (ASC) is a validated patient-reported questionnaire designed to evaluate cancer survivors' concerns across multiple domains (e.g., physical, emotional, social, and existential concerns). Total scores range from 0 to 100, with higher scores indicating greater survivor concerns (worse outcomes) and lower scores indicating fewer concerns (better outcomes).
Time frame: From enrollment to the end of study at 12 months
Patient-Reported Outcome - Decision Regret Scale (DRS)
Decision regret will be assessed using the Decision Regret Scale (DRS), a validated patient-reported questionnaire measuring distress or remorse after a healthcare decision. Scores are transformed to a 0-100 scale, with higher scores indicating greater decision regret (worse outcome) and lower scores indicating less regret (better outcome).
Time frame: From enrollment to the end of study at 12 months
Changes in thyroid biochemical markers over time, including:
Thyroid-stimulating hormone (TSH) Free T4 (if TSH abnormal) Thyroglobulin Thyroglobulin antibody levels
Time frame: From enrollment to the end of study at 12 months.
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — De-identified individual participant data (IPD) from this study may be shared with qualified researchers upon reasonable request. Data sharing will be considered after completion of the primary analyses and publication of the main study results. Shared data will exclude all direct identifiers and will comply with institutional policies, REB requirements, and applicable privacy legislation. Requests will be reviewed by the study Principal Investigator to ensure scientific validity, ethical appropriateness, and alignment with the original consent. Data will be shared under a data-sharing agreement outlining the permitted use of the data, data security requirements, and restrictions on re-identification or further sharing.
Supporting information: Study protocol, Sap, Icf, Csr
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Health Network, Toronto